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ABSTRACT 
TH17 CELL-ASSOCIATED RESPONSE TO BORRELIA BURGDORFERI 
OUTER SURFACE PROTEIN A 
 
by 
 
Megan E. Johnson 
 
The University of Wisconsin-Milwaukee, 2014 
Under the Supervision of Dean T. Nardelli, Ph.D. 
 
Arthritis is a common symptom of Lyme disease, a debilitating condition resulting 
from infection with Borrelia burgdorferi. A protein found on the surface of B. 
burgdorferi, outer surface protein A (OspA), is known to elicit an inflammatory 
immune response involving T helper cells. T helper 17 (Th17) cells are 
associated with the inflammatory cytokines interleukin-17 (IL-17) and interleukin-
23 (IL-23) and have been implicated in the development of Lyme arthritis. The 
objective of this thesis is to provide further characterization of the immune 
response to B. burgdorferi OspA. The central hypothesis of this thesis is: 
Vaccination with OspA will predispose mice to developing a Th17 cell response 
and IL-17-dependent hind paw swelling following stimulation with live 
spirochetes. This hypothesis was tested by pursuing the following specific aims: 
1) Determine the ability of OspA to induce a Th17 response, and 2) Determine 
the ability of OspA to induce IL-17-dependent inflammation. Our hypothesis was 
partially supported by data collected in this study. In vitro incubation of B. 
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burgdorferi-stimulated splenic cells from OspA-vaccinated mice with various 
Th17-associated cytokine antibodies demonstrated a strong development of 
Th17 cell activity, particularly in mice deficient in the anti-inflammatory cytokine 
interleukin-10 (IL-10). While OspA-vaccinated, B. burgdorferi-infected wild-type 
mice treated with anti-IL-17 antibodies exhibited less swelling than untreated 
controls, this was not observed among IL-10-deficient mice. Collectively, these 
results suggest that OspA may promote Th17 cell activity following B. burgdorferi 
exposure in a murine model.   
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CHAPTER 1: INTRODUCTION 
 
I. BACKGROUND 
1. Lyme Disease 
Lyme disease is a debilitating multi-symptom condition resulting from infection 
with the spirochete Borrelia burgdorferi and is the most common arthropod-borne 
infectious disease in the United States (Steere et al. 2004). A recent press 
release from the Centers for Disease Control and Prevention estimated that 
nearly 300,000 Americans develop Lyme disease each year (CDC 2013a), which 
is a ten-fold increase in incidence than was previously thought. This increased 
estimate in the number of cases of Lyme disease was reached through analysis 
of medical claims data and surveys of patients and clinical laboratories (CDC 
2013b).  
The incubation period of B. burgdorferi following transmission from an infected 
tick to a human host may last days to months before any clinical manifestations 
appear (Steere et al. 2004). It is thought that this incubation period occurs partly 
due to the bacterium’s evasion of the host’s immune system, resulting in 
dissemination throughout the body’s tissues. The level of dissemination of the 
spirochete, as well as the duration of infection, can result in different stages and 
severities of clinical manifestations. B. burgdorferi has not been shown to 
produce any toxins that would result in disease; instead, clinical manifestations 
occur due to the host’s immune response to the bacterium (Steere et al. 2004). 
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There are three typical stages of Lyme disease: early localized, early 
disseminated, and late-stage disease (Murray and Shapiro 2010). Localized 
infection is characterized by the presentation of a cutaneous “bull’s eye” rash 
referred to as erythema migrans (EM). The presentation of an EM lesion occurs 
in approximately 70% of Lyme diseases patients (Smith et al. 2002). Other 
common manifestations that often accompany an EM lesion in early localized 
infection are general flu-like symptoms such as fever, fatigue, and neck stiffness 
(CDC 2013a). 
If appropriate treatment is not given in a timely manner, the spirochetes 
disseminate from the original infection site to many different tissues throughout 
the body, which may lead to a wide array of multi-system disorders. The major 
body sites affected by the dissemination of the spirochete include the skin, joints, 
heart, and nervous system. The most common clinical symptoms that present in 
this secondary stage of infection include secondary EM lesions, meningitis, 
cardiac abnormalities, facial nerve palsy, encephalitis, and migratory pain in large 
joints (Wright et al. 2012). 
The symptoms of late disseminated Lyme disease tend to subside from the 
generalized systemic symptoms seen in early disseminated infection, with a few 
relatively common symptoms persisting. Neurological impairments affect a small 
portion of people at this stage and tend to present as difficulty sleeping, mild 
cognitive impairment, and changes in personality (Wright 2012). A more common 
manifestation of late disseminated Lyme disease is arthritis, which can develop 
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within weeks to months after infection with B. burgdorferi (Steere et al.1987, 
Nardelli et al. 2008a). While many of these symptoms can cause permanent or 
recurring damage that can adversely affect quality of life, Lyme disease is not 
considered to be fatal (Wright 2012). 
 2. Transmission of B. burgdorferi and Role of Outer Surface Protein A 
B. burgdorferi is transmitted to an animal reservoir (commonly small rodents, 
deer, and birds) via deer ticks (Ixodes scapularis) in the northeastern and north-
central United States, while western blacklegged ticks (I. pacificus) are the most 
common vectors in the Pacific coast region of the United States. While these 
geographic regions have the highest incidences of Lyme disease, cases have 
been reported in nearly every state (CDC 2013a). There are three main life 
stages of the Ixodes tick- larva, nymph, and adult- and all require feeding from 
animal reservoirs in order to survive. Ixodes nymphs are the most common life 
stage of the tick that transmits B. burgdorferi and are most active during the 
spring and summer months (CDC 2013a). Despite this seasonality, people can 
become infected at any time of the year by ticks of any of the three life stages. 
The movement of animal reservoirs and the population density of infected ticks 
are important factors in the expanding endemic areas of Lyme disease 
throughout the country (Steere 2001; Hamer et al. 2011). 
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Interactions between the spirochete, tick vector, and host are important to the 
dissemination of the bacteria. B. burgdorferi is found within the midgut of infected 
Ixodes ticks and is transferred to a host upon the intake of a blood meal. An 
Ixodes tick itself can become infected by feeding on a mammal infected with B. 
burgdorferi. A lipoprotein and virulence factor found on B. burgdorferi, outer 
surface protein A (OspA), has been found to be upregulated in the unfed tick 
midgut and downregulated in response to factors associated with mammalian 
blood (Schwan & Piesman 2000). Expression of OspA is necessary for B. 
burgdorferi attachment to the tick midgut, and the downregulation of OspA allows 
for movement of the spirochete into the host. OspA is again expressed later in 
untreated disease, as antibodies to OspA have been found in untreated patients 
infected with B. burgdorferi for several years (Schutzer et al. 1994; Akin et al. 
1999). Expression of OspA during late infection has important implications for the 
symptoms of Lyme disease, as inflammatory, OspA-specific T cells are found in 
humans with Lyme arthritis, including antibiotic-refractory disease (Gross et al. 
1998). 
3. Diagnosis of Lyme Disease 
The diagnosis of Lyme disease is based partially on the symptoms of patients 
and whether they reside in or visited an endemic area. In the event of a 
recognizable EM lesion, a physician may begin therapy without performing 
serological tests, as further testing is not necessary or recommended (Nadelman 
and Wormser 1998). Unlike many other bacterial infections, a simple complete 
blood count does not aid in diagnosing Lyme disease, as many indicators of 
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infection, such as white blood cell count, hematocrit, and creatinine, are not 
affected by B. burgdorferi (Bratton et al. 2008). 
The CDC currently recommends a two-tier testing method using a patient’s 
serum for the diagnosis of Lyme disease for patients that may present with 
symptoms in the absence of a defined EM lesion. The first test, which is 
performed for screening purposes, is an enzyme-linked immunosorbent assay 
(ELISA) or an indirect fluorescent antibody test (CDC 2013a). These tests are 
sensitive but not specific (Bratton et al. 2008), so a positive result from one of 
these tests requires further analysis using Western blotting, which provides 
serum immunoglobulin M (IgM) or immunoglobulin G (IgG) results specific for 
certain borrelial proteins. A positive result from both tiers of this testing method 
has a relatively high level of accuracy for diagnosing infection, with a false-
positive rate of approximately 5% (Magnarelli et al. 1990). In cases in which 
neurological impairment is noted, cerebrospinal fluid is often collected for 
assessment of borrelial antibodies (Halperin 2010). One drawback to serological 
methods of detecting B. burgdorferi is a difficulty to distinguish between a current 
and past infection, as high antibody titers may last for several years (Feder et al. 
1992).  
4. Current Treatments and Therapies 
Treatment is recommended only for patients with a high probability of having 
Lyme disease. For example, if patients suspect they have been bitten by a tick 
and do not experience flu-like symptoms or the presence of an EM lesion, 
prophylaxis antibiotic treatment is not recommended (Wormser et al. 2006). 
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However, oral antibiotics, such as cefuroxime axetil, amoxicillin, or doxycycline, 
are given upon diagnosis and usually clear infection within a month for most 
diagnosed patients (Murray and Shapiro 2010). Patients who experience cardiac 
or neurological impairments may be treated with intravenous drugs such as 
ceftriaxone or penicillin (CDC 2013a).  However, some patients do not receive 
antibiotics because they are not formally diagnosed (Steere et al. 1994), while 
the symptoms of some infected persons receiving antibiotics will not respond to 
treatment. These latter patients can develop what has been referred to as post-
Lyme disease syndrome (Wormser et al. 2006). These patients can have 
subjective symptoms of Lyme disease six months or longer following the 
recommended antibiotic therapy, such as mild neurologic impairment, or more 
commonly, arthritis (Steere et al. 1987). 
5. Lyme Arthritis 
Arthritis, a common symptom of Lyme disease, has been estimated to affect 
approximately 60% of untreated, infected patients (Steere et al. 1994). Antibiotic 
therapy usually resolves the arthritis, but nearly 10% of these patients may still 
experience a severe, debilitating arthropathy following the recommended 
treatment. This antibiotic-refractory Lyme arthritis can persist periodically for 
months or years before resolution occurs (Wormser et al. 2012). 
T helper 1 (Th1) cells are involved in the induction of a significant inflammatory 
response leading to arthritis following B. burgdorferi infection (Yssel et al. 1991). 
Studies have demonstrated that high production of the Th1-associated cytokines 
interferon-gamma (IFN- γ) and interleukin-12 following B. burgdorferi infection 
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correlates with increased joint swelling in mice, while administration of 
interleukin-4, a T helper 2 (Th2) cytokine, results in decreased swelling in mice 
(Matyniak & Reiner 1995; Anguita et al. 1996; Keane-Myers et al. 1996). 
However, subsequent studies demonstrated that Lyme arthritis can be induced in 
the absence of IFN-γ in mice, suggesting that Th1 cells are not absolutely 
required for development of disease (Brown & Reiner et al. 1999, Christopherson 
et al. 2003).  
Another pro-inflammatory cytokine, interleukin-17 (IL-17), was presented as 
another possible candidate for the development of Lyme arthritis. Specifically, 
IFN-γ-deficient mice that were treated with anti-IL-17 antibodies did not develop 
arthritis in a model in which vaccine-primed mice were infected with live 
spirochetes (Burchill et al. 2003; Nardelli et al. 2004). Additionally, stimulation 
with B. burgdorferi has been shown to produce IL-17 in human (Infante-Duarte et 
al. 2000) and murine (Kotloski et al. 2008) cell cultures in vitro. IL-17 can cause 
the infiltration of a large array of pro-inflammatory molecules that have been 
shown to contribute to tissue damage, including interleukin-6 (IL-6), interleukin-8, 
granulocyte colony-stimulating factor, and monocyte chemoattractant protein-1 
(Aggarwal et al. 2002).  
IL-17 is produced, in large part, by T helper 17 (Th17) cells. Th17 cells are 
implicated in inflammatory responses in several diseases, including rheumatoid 
arthritis, psoriasis, Crohn's disease, and multiple sclerosis (Miossec 2009). Th17 
cells have also been suggested to be involved in development of Lyme arthritis in 
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both mice and humans (Nardelli et al. 2008a; Codolo et al. 2008). It was shown 
that a combination of IL-6 and transforming growth factor-beta (TGF-β) support 
Th17 cell differentiation (Bettelli et al. 2006). As a result, previous studies 
involving IL-17 in B. burgdorferi-infected murine models of arthritis were 
extended to assess the involvement of Th17 cells and cytokines. Blocking both 
IL-6 and TGF-β was shown to reduce histopathologic changes compared to 
untreated control mice in a vaccination/infection murine model; however, blocking 
IL-6 and TGF-β in addition to IL-17 completely prevented the development of 
arthritis (Nardelli et al. 2008b). Importantly, humans with Lyme arthritis exhibit 
increased production of IL-6, TGF-β, and IL-17, suggesting the involvement of 
Th17 cells (Codolo et al. 2008; Codolo et al. 2013). Interestingly, administration 
of anti-IL-6 antibodies alone to B. burgdorferi-vaccinated and infected mice has 
been observed to increase the severity of disease progression, which may 
suggest an enhancement of Th17 activity without IL-6 production (Nardelli et al. 
2008b).  
Interleukin-23 (IL-23), a survival factor for Th17 cells (Bettelli et al. 2006), is 
expressed in response to bacterial lipopolysaccharides and was found to 
stimulate proliferation of IL-17-producing T cells (Aggarwal et al. 2003). 
Additionally, blockage of IL-23 prevented the induction of Lyme arthritis in a 
mouse model of disease (Kotloski et al. 2008). Knauer et al. (2007) 
demonstrated a lack of IL-17 secretion from spleen cells of IL-23-deficient mice 
following in vitro stimulation with several borrelial proteins, suggesting that IL-23 
is required for a Th17 cell response in B. burgdorferi infection. Recently, high IL-
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23 levels also have been determined to be closely associated with individuals 
presenting with an EM lesion who experience arthritis even after antibiotic 
therapy (Strle et al. 2014). These findings add to the evidence for Th17 cells as 
potential contributors to the development of Lyme arthritis. 
As described previously, some patients with Lyme arthritis continue to exhibit 
disease even after receiving antimicrobial therapy. While it is not fully understood 
why these individuals still develop Lyme arthritis following the recommended 
antibiotic treatment, several possible explanations have been proposed. Some 
studies suggested that an autoimmune response is induced in a small subset of 
the population with major histocompatibility complex class II histocompatibility 
leukocyte antigen (HLA)-DR4, which leads to an increased T cell response to 
OspA (Kalish et al. 1993; Chen et al. 1999; Steere et al. 2001b). In addition, 
bystander activation may also explain sustained arthritis in individuals infected 
with B. burgdorferi (Steere and Glickstein 2004). Another explanation that has 
been proposed is referred to as the amber theory. This theory suggests that dead 
B. burgdorferi spirochetes and their fragments can be found in articular 
connective tissues of infected individuals (Wormser et al. 2012). It is possible that 
non-viable spirochetes may express adhesion molecules that aid in binding to 
these connective tissues. The ability of these non-viable spirochetes to perform 
such functions may be possible in bacteria that were not killed by antibiotics but, 
rather, acted upon by the host’s immune system (Wormser et al. 2012). Over 
time, fragments are released from these host matrices into the joint tissue, 
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eliciting an inflammatory response in different joints. This may explain why 
antibiotic therapy is ineffective in resolving arthritis in some patients.   
The immune response to OspA may be involved in the induction of Lyme 
arthritis. Vaccination with recombinant OspA (rOspA) and subsequent infection 
with B. burgdorferi has been found to result in severe destructive arthritis in 
hamsters (Croke et al. 2000). In addition, blood samples from untreated 
individuals infected with B. burgdorferi were assessed for immunoglobulin levels 
during the onset of an EM lesion and during late arthritic symptoms (Akin et al. 
1999). While all patients had relatively low levels of OspA-reactive IgM and IgG 
in early B. burgdorferi infection, 60% of patients exhibited increased OspA IgG 
responses during late-stage arthritis. Interestingly, these patients were more 
likely to have the HLA-DR4 allele (Akin et al. 1999). A study identifying OspA 
using a Western blot did not identify IgM responses during EM presentation and 
only in a small percentage (12%) of individuals with meningitis (Dressler et al. 
1993). However, the presence of OspA-specific IgG was found during later 
arthritic and neurological impairments in approximately 40% of individuals, 
compared to 2% of the control population. This suggests that OspA-specific 
responses are typically downregulated during early infection but are then 
pronounced later in the immune response to B. burgdorferi. In addition, OspA 
antibodies and OspA-reactive T cells have been isolated in individuals with Lyme 
arthritis, suggesting that the presence of OspA may be associated with the 
development of this symptom. 
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Those patients that do not respond to antibiotic therapy often have increased 
numbers of Th1 cells that react to OspA, as it is upregulated in later infection, 
which may lead to inflammatory events such as arthritis (Gross et al. 1998). It 
has been believed that an inflammatory response to a specific epitope, OspA165-
173, may contribute to the development of autoimmune events in antibiotic-
resistant arthritis (Steere et al. 2011). The specific borrelial components that 
stimulate the production of Th17-associated cytokines, in particular, are not fully 
understood. Infante-Duarte et al. (2000) demonstrated that outer surface 
lipoproteins are involved in the production of IL-17 in vitro. In addition, Codolo et 
al. (2008) showed the involvement of borrelial neutrophil-activating protein A 
(NapA) in Th17 inflammation. Interestingly, Codolo et al. (2008) observed that 
while NapA robustly stimulated IL-23 production by neutrophils and monocytes, 
OspA did not. Further investigation into the pathways involving IL-17 in response 
to OspA would provide a better understanding of the immune response to B. 
burgdorferi and subsequent disease resolution. 
 
6. Vaccines 
i. Canine Vaccines 
There is currently no vaccine for Lyme disease approved for human use on the 
market. There are, however, multiple canine vaccines on the market: adjuvanted 
or non-adjuvanted rOpsA, or monovalent or bivalent bacterin. The vaccines are 
targeted mostly to induce anti-OspA antibodies. However, the efficacy and safety 
of these vaccines have been questioned; the various vaccines have a reported 
efficacy of 60-90%, and approximately 2% of dogs receiving the vaccines have 
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had adverse reactions (Littman et al. 2006). More recent developments in canine 
vaccines have shown that vaccinating with a bacterin that induces both anti-
OspA and anti-OspC antibodies significantly reduces infection with B. burgdorferi 
and clinical manifestations associated with Lyme disease in beagles for at least 
one year (LaFleur et al. 2009; LaFleur et al. 2010). 
While 95% of dogs that are infected with B. burgdorferi are asymptomatic, many 
veterinarians still recommend vaccinating dogs living in or traveling to endemic 
areas (Levy & Magnarelli 1992). The reason for this recommendation stems from 
the small percentage of dogs that are at a higher risk for adverse reactions to B. 
burgdorferi. These adverse reactions include arthritis, neuropathy, and 
nephropathy and tend to present in Labradors and Golden Retrievers more than 
other breeds (Littman et al. 2006). A debate in the veterinary community is 
whether the risk of arthritis or other clinical manifestations from infection with B. 
burgdorferi outweighs the risk of potentially developing an adverse reaction to the 
vaccine. 
ii. Human Vaccines 
Two rOspA vaccines for Lyme disease were developed for humans in 1998 
(Steere et al. 1998; Sigal et al. 1998). While both used OspA as the main 
component, the main variance between the two was that one contained an 
aluminum hydroxide adjuvant, while the other did not (Aronowitz 2012). The 
proposed mechanism of the vaccines was for the body to produce protective 
antibodies against OspA that would be ingested by a tick upon biting a human, 
killing B. burgdorferi in the tick midgut before the spirochete could enter the body 
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(Poland 2011). Clinical trials occurred over a year’s time, with close observation 
of over 10,000 participants living in endemic areas and no adverse effects 
reported (Steere 1998; Sigal et al. 1998). One vaccine was made available for 
public use, but was removed from the market due to low demand. According to 
the Vaccine Adverse Events Reporting System, a very small percentage of 
recipients had adverse reactions to the Lyme vaccine, including arthritis, flu-like 
symptoms, gastrointestinal disease, and paralysis (Geier & Geier 2002). Another 
study found that some recipients of the human vaccine developed neuropathy 
and cognitive impairment shortly after vaccination, regardless of prior B. 
burgdorferi infection, that may have primed the immune system to cause an 
overly robust immune response (Latov et al. 2004). In a study performed on 
hamsters following the release of the human Lyme disease vaccine, vaccination 
with OspA and subsequent infection with B. burgdorferi was found to elicit 
destructive arthritis and cartilage degradation (Croke et al. 2000).  
Questions surrounding the antibody response that develops following vaccination 
with OspA have also been raised (Nardelli et al. 2009). Other rOspA vaccines 
showed high levels of protective, borreliacidal antibodies following vaccination, 
but, importantly, waned shortly thereafter, requiring multiple boosters (Keller et 
al. 1994; Padilla et al. 1994). In addition, antibodies induced in response to 
rOspA present a problem with current diagnostic methods. rOspA-specific 
antibodies have been shown to interfere with the two-tier diagnostic system 
recommended by the Centers for Disease Control and Prevention, even years 
after receiving the vaccine (Fawcett et al. 2004). Some vaccine recipients may 
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test positive for Lyme disease with these serological methods, even if they have 
never been infected with B. burgdorferi. This presents an important point to 
address when developing a vaccine against B. burgdorferi, as being able to 
confirm the infection of an individual is vital for proper treatment. Modification of 
the vaccine or method of diagnosis must allow for proper identification of an 
infected individual who may have been vaccinated. 
There still remains a debate on what components are necessary in a human 
vaccine for lasting, safe protection against B. burgdorferi. A recent study 
described the use of a multivalent OspA vaccine, no longer containing the 
OspA165-173 epitope, that could possibly protect against various Borrelia species 
(Wressnigg et al. 2013). This vaccine has been tested in a clinical trial with 300 
participants with some mild adverse reactions, but also with relatively high 
antibody titers for Borrelia species. A non-adjuvanted vaccine resulted in lower 
antibody production than adjuvanted vaccines, suggesting that an adjuvant is 
required for a robust antibody response (Wressnigg et al. 2013). Despite these 
findings, more information about this vaccine is needed, including assessing the 
duration of protection, comparing risks in age groups, and determining its efficacy 
using a larger sample size. 
Other vaccines have been suggested, including ones comprised of multiple outer 
surface proteins, such as outer surface protein C (OspC), as major components. 
Specifically, OspC C7, an immunodominant peptide found on the carboxyl-
terminal end of the OspC protein, has been shown to be homologous among 
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different Borrelia species (Lovrich et al. 2005). No human Lyme vaccines have 
contained OspC peptides; however, canine vaccines including OspC peptides 
have been shown to provide more comprehensive protection than those 
containing OspA alone (LaFleur et al. 2010). A better understanding of the 
mechanisms of the immune response following borrelial vaccination may be 
helpful in identifying reliable and safe Lyme vaccine candidates. 
 
II. HYPOTHESIS AND SPECIFIC AIMS  
Arthritis is a common symptom of patients with Lyme disease and can have 
serious effects on the quality of life for those living with the condition. Although 
OspA was the main candidate for a Lyme disease vaccine, studies have shown 
that OspA-reactive inflammatory T cells are present in patients with Lyme arthritis 
(Gross et al. 1998), suggesting a role for OspA in the development of the 
inflammatory response. In support of this, hamsters vaccinated with OspA and 
challenged with B. burgdorferi displayed severe destructive arthritis (Croke et al. 
2000).  
Th17 cells are involved in inducing inflammatory responses in several diseases, 
including, possibly, Lyme arthritis (Nardelli et al. 2008a; Codolo et al. 2008). IL-
17 has been shown to be an immune factor involved in the development of 
experimental Lyme arthritis (Burchill et al. 2003; Nardelli et al. 2004). In addition, 
blocking IL-23, a survival factor for Th17 cells, reduced IL-17 production and 
arthritis in a murine model (Kotloski et al. 2008). What is unknown, however, is 
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whether a Th17-associated immune response is generated in response to B. 
burgdorferi OspA. Further investigation into the mechanisms of the IL-17 
response to B. burgdorferi OspA would provide a better understanding of the 
immune response to B. burgdorferi overall, as well as aid in developing safe and 
effective vaccines for Lyme disease.  
The objective of this thesis is to provide further characterization of the immune 
response to B. burgdorferi OspA. The hypothesis of this thesis is: Vaccination 
with OspA will predispose mice to developing a Th17 cell response and IL-17-
dependent hind paw swelling following stimulation with live spirochetes. 
This hypothesis was tested by pursuing the following specific aims: 
1. Determine the ability of OspA to induce a Th17 response. The 
working hypothesis of this specific aim is: Vaccination with OspA will prime 
mice to produce a Th17 cell response following stimulation with B. 
burgdorferi. 
2. Determine the ability of OspA to induce IL-17-dependent 
inflammation. The working hypothesis of this specific aim is: Vaccination 
with OspA will prime mice to develop IL-17-dependent paw swelling after 
infection with B. burgdorferi. 
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CHAPTER 2: MATERIALS AND METHODS 
I. MICE  
Male wild-type and interleukin-10 (IL-10)-deficient C57BL/6 mice were provided 
by J.-A. Lyons (University of Wisconsin-Milwaukee). Mice were housed at the 
University of Wisconsin-Milwaukee (UWM) Animal Resource Center and 
received food and water ad libitum. These strains of mice were used due to their 
different responses to B. burgdorferi infection. Following infection with B. 
burgdorferi, wild-type C57BL/6 mice develop mild to moderate arthritis, while 
C57BL/6 mice lacking IL-10, an-anti-inflammatory cytokine, develop severe 
disease (Brown et al. 1999; Hansen et al. 2013). Procedures were approved by 
the UWM Institutional Animal Care and Use Committee. 
 
II. VACCINATION OF MICE 
rOspA from B. burgdorferi 297 was provided by S. Callister (Gundersen Medical 
Center, La Crosse, WI). Groups of three mice were vaccinated in each inguinal 
region with 50 μg OspA (0.25 mL) in 1% aluminum hydroxide. Sham-vaccinated 
control mice were injected similarly with aluminum hydroxide but without OspA.  
 
III. INFECTION OF MICE 
B. burgdorferi 297 organisms were provided by S. Callister (Gundersen Medical 
Center, La Crosse, WI). Organisms were enumerated and assessed for viability 
using darkfield microscopy. Twenty-one or 14 days after vaccination, some wild-
type and IL-10-deficient mice, respectively, were injected with 105 B. burgdorferi 
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strain 297 organisms in Barbour-Stoenner-Kelly (BSK) medium (0.05 mL) in a 
hind paw. Non-infected control mice received injections of 0.05 mL BSK medium. 
Some OspA-vaccinated mice received no B. burgdorferi or BSK medium. 
 
IV. ANTIBODY TREATMENT 
On the day following infection, groups of vaccinated and infected mice were 
injected in the left hind paws with 2.5 μg of anti-IL-17 antibody (eBioscience, San 
Diego, CA) in 0.05 mL phosphate buffered saline (PBS). Anti-IL-17 antibody 
administration continued every other day until the mice were euthanized at day 8 
after infection. Non-treated control mice were injected with 2.5 μg of isotype 
control antibodies (eBioscience) in 0.05 mL PBS in a similar manner. 
 
V. CELL CULTURE  
At days 14 and 21 following vaccination with OspA, some non-infected IL-10- 
deficient and wild-type mice, respectively, were euthanized by isoflurane 
inhalation followed by cervical dislocation, and their spleens were harvested. In 
another study, spleens were obtained from uninfected, OspA-vaccinated mice, B. 
burgdorferi-infected, OspA-vaccinated mice, and anti-IL-17 antibody-treated, 
OspA-vaccinated and B. burgdorferi-infected mice eight days after infection. 
Spleens were passed through 100 µm cell strainers into cold RPMI 1640 medium 
supplemented with L-glutamine and 25mM HEPES (Cellgro; Corning) and then 
enumerated by trypan blue exclusion. 5 x 105 spleen cells from non-infected, 
OspA-vaccinated mice were incubated (35˚C, 5% CO2) in duplicate in the 
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presence or absence of 105 viable B. burgdorferi organisms in a total volume of 
0.5 mL. In addition, stimulated cells were incubated in the presence of 10 µg (20 
µg/mL) of anti-IL-6 antibodies, anti-IL-23 antibodies, or isotype control antibodies 
(eBioscience) for 24 and 48 hours. Similarly, stimulated cells from OspA-
vaccinated mice were incubated in the presence of anti-CD4 antibodies or 
isotype control antibodies (10 µg/mL or 20 µg/mL; eBioscience) for 24 and 48 
hours. In another study, spleen cells from uninfected, OspA-vaccinated mice, B. 
burgdorferi-infected, OspA-vaccinated mice, and anti-IL-17 antibody-treated, 
OspA-vaccinated and B. burgdorferi-infected mice were incubated without 
stimulation in RPMI medium at 35˚C in 5% CO2 for 4 or 24 hours. 
 
VI. ELISAS 
The amounts of IL-17 and IL-23 secreted in cell culture supernatants were 
assessed using mouse IL-17 and mouse IL-23p19 Ready-SET-Go! Kits from 
eBioscience. The assays were performed according to the manufacturer’s 
instructions. Plates were read at 450 nm and values from each well were 
reported as absorbance readings, which were then calculated to cytokine 
concentrations (pg/mL supernatant) using a standard curve. 
 
VII. ASSESSMENT OF PAW SWELLING  
The thickness and width of tibiotarsal joints of uninfected, OspA-vaccinated mice, 
B. burgdorferi-infected, OspA-vaccinated mice, and anti-IL-17 antibody-treated, 
OspA-vaccinated and B. burgdorferi-infected mice were measured using a digital 
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caliper. Paws were measured prior to infection and on days 3, 6, and 8 
thereafter. These measurements were used to determine the changes in swelling 
as a result of infection following vaccination with OspA. Hind paws were removed 
and fixed in 10% buffered formalin for future examination by an unbiased, board-
certified pathologist.  
 
VIII. BORRELIACIDAL ANTIBODY ASSAY  
Serum was collected on the day of euthanasia by performing an intracardiac 
blood draw and then centrifuging the blood at 500 rpm for 20 minutes to separate 
serum. Equal volumes of serum were pooled within each group of mice, and 
samples were filtered using a 0.2 µm filter, heated to 56°C for 30 minutes, and 
then cooled to 35°C. The sera were diluted 1:20 in BSK medium and then further 
diluted serially with BSK medium (to 1:40,960). 104 B. burgdorferi strain 297 
organisms and 20 µl of guinea pig serum reconstituted in BSK medium were 
added to each heat-inactivated serum sample and then incubated for 18 hours at 
35°C. The presence of viable spirochetes was determined by darkfield 
microscopy using 20-30 fields of view. The reciprocal of the greatest dilution with 
no motile spirochetes was considered the borreliacidal antibody titer. 
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CHAPTER 3: RESULTS 
 
I. Specific Aim 1:  Determine the ability of OspA to induce a Th17 
response. 
IL-17 production by cells of OspA-vaccinated wild-type mice. Spleen cells 
harvested from sham- or OspA-vaccinated wild-type mice were either 
unstimulated or stimulated with B. burgdorferi for 24 or 48 hours. Unstimulated 
cells from wild-type, sham-vaccinated mice produced between 20.1 and 37.4 pg 
IL-17/mL supernatant after 24 hours (Figure 1). Stimulation of these cells with B. 
burgdorferi for 24 hours caused a decrease in IL-17 production in 2 of 3 samples 
(37.4 to 27.3 pg, 27%; 25.7 to 14.7 pg, 43%). In 1 of the 3 samples, however, 
stimulation with B. burgdorferi induced a slight increase (20.1 to 21.2 pg, 5%) in 
IL-17 production. Similarly, unstimulated cells from wild-type OspA-vaccinated 
mice produced between 13.1 and 31.8 pg IL-17/mL supernatant after 24 hours 
(Figure 1). Stimulation of these cells with B. burgdorferi for 24 hours resulted in a 
decrease in IL-17 production in all 3 samples (31.8 to 27.1 pg, 15%; 20.2 to 13.0 
pg, 35%; 13.1 to 11.1 pg, 15%). 
After 48 hours of incubation, unstimulated cells from wild-type, sham-vaccinated 
mice produced between 4.5 and 25.1 pg IL-17/mL supernatant (Figure 1). 
Stimulation of these cells with B. burgdorferi for 48 hours resulted in an increase 
in IL-17 production in 2 of the 3 samples (25.1 to 39.0 pg, 55%; 4.5 to 13.4, 
197%). In 1 of the 3 samples, however, stimulation of sham-vaccinated cells with 
B. burgdorferi led to a slight decrease (20.2 to 18.9 pg, 6%) in IL-17 production 
compared to unstimulated cells. Additionally, unstimulated cells from wild-type, 
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OspA-vaccinated mice produced between 4.5 and 9.9 pg IL-17/mL supernatant 
after 48 hours (Figure 1). Stimulation of these cells with B. burgdorferi for 48 
hours resulted in an increase in IL-17 production in all 3 samples. The increase in 
IL-17 production by one of these samples was minimal (9.9 to 10.2 pg, 3%), 
while the increases in the other two were much higher (8.0 to 41.3, 416%; 4.5 to 
31.1, 591%).  
 
 
 
 
IL-17 production by cells of OspA-vaccinated, IL-10-deficient mice. Spleen cells 
harvested from sham- or OspA-vaccinated, IL-10-deficient mice were either 
unstimulated or stimulated with B. burgdorferi for 24 or 48 hours. Unstimulated 
Figure 1. IL-17 production by spleen cells of 3 sham-vaccinated 
or OspA-vaccinated wild-type mice at 24 hours and 48 hours of 
incubation in the presence or absence of B. burgdorferi. 
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cells from IL-10-deficient, sham-vaccinated mice produced between undetectable 
and 172.7 pg IL-17/mL supernatant after 24 hours (Figure 2). Stimulation of 
these cells with B. burgdorferi for 24 hours caused an increase in IL-17 
production in 2 of 3 samples (58.1 to 74.0 pg, 27%; 0 to 22.0 pg). In a third 
sample, however, IL-17 production was reduced after stimulation with B. 
burgdorferi (172.7 pg to 86.4 pg, 50%). Additionally, spleen cells harvested from 
OspA-vaccinated, IL-10-deficient mice produced between undetectable levels 
and 228.6 pg IL-17/mL supernatant after 24 hours (Figure 2). Stimulation of 
these cells with B. burgdorferi after 24 hours resulted in an increase of IL-17 
production in 2 of the 3 samples (52.7 to 74.2 pg, 41%; 0.0 to 7.3 pg). Cells from 
a third sample displayed slightly reduced (228.6 to 214.2 pg, 6%) IL-17 
production following 24 hours of stimulation with B. burgdorferi. 
After 48 hours of incubation, unstimulated cells from sham-vaccinated, IL-10-
deficient mice produced between 6.8 and 68.9 pg IL-17/mL supernatant (Figure 
2). Stimulation of these cells with B. burgdorferi for 48 hours resulted in an 
increase in IL-17 production in all 3 samples (68.9 to 101.4 pg, 47%; 6.8 to 15.0 
pg, 121%; 54.4 to 120.4 pg, 121%). In addition, unstimulated cells from OspA-
vaccinated, IL-10-deficient mice produced between undetectable levels and 
120.4 pg IL-17/mL supernatant after 48 hours (Figure 2). IL-17 production 
increased in 1 of the 3 samples (0 to 208.9 pg IL-17/mL supernatant). However, 
upon stimulation with B. burgdorferi for 48 hours, cells from 2 of the 3 samples 
produced decreased levels of IL-17 (83.9 to 70.7 pg, 16%; 120.4 to 8.2 pg, 93%).  
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Effect of IL-6 on IL-17 production by cells of OspA-vaccinated wild-type mice. 
Spleen cells harvested from wild-type, sham- and OspA-vaccinated mice were 
stimulated with B. burgdorferi and incubated with anti-IL-6 antibodies for 24 or 48 
hours. As stated previously, untreated, B. burgdorferi-stimulated cells from wild-
type, sham-vaccinated mice produced between 14.7 and 27.3 pg IL-17/mL 
supernatant after 24 hours. Treatment of stimulated cells from sham-vaccinated 
mice with anti-IL-6 antibodies for 24 hours resulted in an increase of IL-17 
production in 2 of the 3 samples (27.3 to 48.4 pg, 77%; 14.7 to 31.2 pg, 112%) 
compared to untreated cells (Figure 3). Conversely, in 1 of 3 samples, anti-IL-6 
Figure 2. IL-17 production by spleen cells of 3 sham-vaccinated 
or OspA-vaccinated, IL-10-deficient mice in the presence or 
absence of B. burgdorferi. 
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antibody caused a 55% decrease in IL-17 production (21.2 to 9.6 pg). Similarly, 
and as stated previously, untreated, B. burgdorferi-stimulated cells from wild-
type, OspA-vaccinated mice produced between 11.1 and 27.1 pg IL-17/mL 
supernatant after 24 hours (Figure 3). Treatment with anti-IL-6 antibodies 
resulted in an increase in IL-17 production from all 3 samples of stimulated cells 
(11.1 to 15.7 pg, 41%; 13.0 to 19.5, 50%; 27.1 to 48.7, 80%) after 24 hours of 
incubation. 
As stated previously, untreated, B. burgdorferi-stimulated cells from wild-type, 
sham-vaccinated mice produced between 13.4 and 39.0 pg IL-17/mL 
supernatant after 48 hours of incubation. Treatment of stimulated cells from 
sham-vaccinated mice with anti-IL-6 antibodies for 48 hours resulted in a 
decrease in IL-17 production in 2 of the 3 samples (18.9 to 17.6 pg, 7%; 39.0 to 
16.0 pg, 59%), while one sample displayed an increase in IL-17 production (13.4 
to 17.4 pg, 31%) compared to untreated cells (Figure 3). Similarly, and as stated 
previously, untreated, B. burgdorferi-stimulated cells from wild-type, OspA-
vaccinated mice produced between 10.2 and 41.3 pg IL-17/mL supernatant after 
48 hours. Cells from OspA-vaccinated mice treated with anti-IL-6 antibodies for 
48 hours displayed a decrease (31.1 to 13.3 pg, 57%; 41.3 to 8.2 pg, 80%) in IL-
17 production in two of the samples compared to untreated cells, while 1 of the 3 
samples exhibited a 192% increase in IL-17 production (10.2 to 29.8 pg). 
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Effect of IL-6 on IL-17 production by cells of OspA-vaccinated, IL-10-deficient 
mice. Spleen cells harvested from IL-10-deficient, sham- and OspA-vaccinated 
mice were incubated with B. burgdorferi and anti-IL-6 antibodies for 24 or 48 
hours. As stated previously, untreated, B. burgdorferi-stimulated cells from IL-10-
deficient, sham-vaccinated mice produced between 22.0 and 86.4 pg IL-17/mL 
supernatant after 24 hours. Treatment of stimulated cells from sham-vaccinated 
mice with anti-IL-6 antibodies for 24 hours resulted in increased IL-17 production 
by all 3 samples (86.4 to 117.7 pg, 36%; 74.0 to 76.0 pg, 3%; 22.0 to 50.1, 
128%) compared to untreated cells (Figure 4). As stated previously, untreated, B. 
burgdorferi-stimulated cells from IL-10-deficient, OspA-vaccinated mice produced 
Figure 3. IL-17 production by anti-IL-6 antibody-treated, B. 
burgdorferi-stimulated spleen cells from 3 sham- or OspA-
vaccinated wild-type mice. 
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between 7.3 and 214.2 pg IL-17/mL supernatant after 24 hours. Treatment of 
stimulated cells from OspA-vaccinated mice with anti-IL-6 antibodies for 24 hours 
resulted in a decrease in IL-17 production in 2 of the 3 samples (214.2 to 102.9 
pg, 52%; 74.2 to 24.7 pg, 62%) (Figure 4). By contrast, in a third sample, anti-IL-
6 antibody treatment caused a 101% increase in IL-17 production (7.3 to 14.7 
pg).  
As described previously, untreated, B. burgdorferi-stimulated cells from IL-10-
deficient, sham-vaccinated mice produced between 15.0 and 120.4 pg IL-17/mL 
supernatant after 48 hours of incubation. Treatment of B. burgdorferi-stimulated 
cells from sham-vaccinated mice with anti-IL-6 antibodies for 48 hours resulted in 
a decrease in IL-17 production in 2 of the 3 samples (120.4 to 95.3 pg, 21%; 
101.4 to 80.5 pg, 21%), while one sample displayed a large increase in IL-17 
production (15.0 to 55.9 pg, 273%) compared to untreated cells (Figure 4). As 
stated previously, untreated, B. burgdorferi-stimulated cells from IL-10-deficient, 
OspA-vaccinated mice produced between 8.2 and 208.9 pg IL-17/mL 
supernatant after 48 hours of incubation. Treatment of stimulated cells from 
OspA-vaccinated mice with anti-IL-6 antibodies for 48 hours resulted in a 
decrease in IL-17 production in 2 of the 3 samples (208.9 to 173.3, 17%; 70.7 to 
undetectable levels, 100%). By contrast, in 1 of the 3 samples, anti-IL-6 antibody 
treatment caused a 413% increase in IL-17 production (8.2 to 42.1 pg) (Figure 4). 
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Effect of IL-23 on IL-17 production by cells of OspA-vaccinated wild-type mice. 
Spleen cells harvested from wild-type, OspA-vaccinated mice were stimulated 
with B. burgdorferi and incubated with anti-IL-23p19 antibodies for 24 or 48 
hours. As described previously, untreated, B. burgdorferi-stimulated cells from 
wild-type, sham-vaccinated mice produced between 14.7 and 27.3 pg IL-17/mL 
supernatant after 24 hours. Treatment of stimulated cells from sham-vaccinated 
mice with anti-IL-23p19 antibodies for 24 hours resulted in a decrease in IL-17 
production in 2 of the 3 samples (27.3 to 12.6 pg, 54%; 21.2 to 3.1 pg, 85%) 
Figure 4. IL-17 production by anti-IL-6 antibody-treated, B. 
burgdorferi-stimulated spleen cells from 3 sham- or OspA-
vaccinated, IL-10-deficient mice. 
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(Figure 5). One of the 3 samples treated with anti-IL-23p19 antibodies displayed 
a 40% increase (14.7 to 20.5 pg) in IL-17 production after 24 hours of incubation. 
Similarly, and as described previously, untreated, B. burgdorferi-stimulated cells 
from wild-type, OspA-vaccinated mice produced between 11.1 and 27.1 pg IL-
17/mL supernatant after 24 hours. Treatment of stimulated, OspA-vaccinated 
cells with anti-IL-23p19 antibodies for 24 hours resulted in a decrease in IL-17 
production in 2 of the 3 samples (27.1 to 17.1 pg, 37%; 11.1 to 6.9 pg,38%) 
compared to untreated cells (Figure 5). One of 3 samples treated with anti-IL-
23p19 antibodies exhibited slightly increased IL-17 production (13.0 to 14.5 pg, 
11%) compared to untreated cells.  
As stated previously, after 48 hours of incubation, untreated, B. burgdorferi-
stimulated cells from wild-type, sham-vaccinated mice produced between 13.4 
and 39.0 pg IL-17/mL supernatant. Stimulated sham-vaccinated cells treated with 
anti-IL-23p19 antibodies for 48 hours displayed a decrease in IL-17 production in 
all three samples (39.0 to 23.6 pg, 39%; 18.9 to 18.5 pg, 2%; 13.4 to 6.1 pg, 
54%) compared to untreated cells (Figure 5).  Similarly, and as stated previously, 
untreated, B. burgdorferi-stimulated cells from wild-type, OspA-vaccinated mice 
produced between 10.2 and 41.3 pg IL-17/mL supernatant after 48 hours of 
incubation. Treatment of stimulated cells from OspA-vaccinated mice with anti-IL-
23p19 antibodies for 48 hours resulted in a consistently large decrease in IL-17 
production in all 3 samples (41.3 to 13.9 pg, 66%; 31.1 to 17.3 pg, 44%; 10.2 to 
5.2 pg, 49%) compared to untreated cells (Figure 5). 
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Effect of IL-23 on IL-17 production by cells of OspA-vaccinated, IL-10-deficient 
mice. Spleen cells harvested from IL-10-deficient, sham- and OspA-vaccinated 
mice were incubated with B. burgdorferi and anti-IL-23p19 antibodies for 24 or 48 
hours. As stated previously, untreated, B. burgdorferi-stimulated cells from IL-10-
deficient, sham-vaccinated mice produced between 22.0 and 86.4 pg IL-17/mL 
supernatant after 24 hours. In one sample, treatment of stimulated cells from 
sham-vaccinated mice with anti-IL-23p19 antibody for 24 hours resulted in a 
notable enhancement of IL-17 production (22.0 to 58.3 pg, 165%; Figure 6). 
Figure 5. IL-17 production by anti-IL-23p19 antibody-treated, B. 
burgdorferi-stimulated spleen cells from 3 sham- or OspA-
vaccinated wild-type mice. 
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However, in another sample, IL-17 production increased minimally (86.4 to 86.9 
pg; 1%). By contrast, anti-IL-23p19 antibody treatment caused a 61% decrease 
in IL-17 production in a third sample (74.0 to 28.6, 61%; Figure 6). As stated 
previously, untreated, B. burgdorferi-stimulated cells from IL-10-deficient, OspA-
vaccinated mice produced between 7.3 and 214.2 pg IL-17/mL supernatant after 
24 hours. In contrast to that which was observed among sham-vaccinated cells, 
treatment of stimulated cells from OspA-vaccinated mice with anti-IL-23 antibody 
for 24 hours caused a substantial decrease in IL-17 production in all 3 samples 
(214.2 to 47.5 pg, 78%; 74.2 to 11.2 pg, 85%; 7.3 to 4.6 pg, 37%) (Figure 6).  
As stated previously, after 48 hours of incubation, untreated, B. burgdorferi-
stimulated cells from IL-10-deficient, sham-vaccinated mice produced between 
15.0 and 120.4 pg IL-17/mL supernatant. Treatment of stimulated cells from 
sham-vaccinated mice with anti-IL-23p19 antibody for 48 hours caused a 
decrease in IL-17 production in 2 of 3 samples (120.4 to 34.2 pg, 72%; 101.4 to 
47.9 pg, 53%) (Figure 6). By contrast, in 1 of 3 samples, anti-IL-23p19 antibody 
caused a 60% increase in IL-17 production (15.0 to 24.0 pg). As stated 
previously, after 48 hours of incubation, untreated, B. burgdorferi-stimulated cells 
from IL-10-deficient, OspA-vaccinated mice produced between 8.2 and 208.9 pg 
IL-17/mL supernatant. Treatment of stimulated cells from OspA-vaccinated mice 
with anti-IL-23p19 antibody for 48 hours caused a substantial decrease in IL-17 
production in 2 of 3 samples (208.9 to 81.6, 61%; 70.7 to 20.6 pg, 71%). By 
contrast, in 1 of 3 samples, anti-IL-23p19 antibody treatment caused a 164% 
increase in IL-17 production (8.2 to 21.7 pg). 
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Effect of anti-CD4 antibodies on production of IL-17 by cells of OspA-vaccinated 
wild-type mice. Spleen cells harvested from wild-type, sham- or OspA-vaccinated 
mice were incubated with B. burgdorferi and with either 10 µg/mL or 20 µg/mL 
anti-CD4 antibodies for 24 or 48 hours. Untreated, B. burgdorferi-stimulated cells 
from wild-type, sham-vaccinated mice produced between 16.2 and 22.0 pg IL-
17/mL supernatant after 24 hours. Treatment of stimulated cells from sham-
vaccinated mice with 10 µg/mL anti-CD4 antibodies for 24 hours resulted in an 
increase in IL-17 production in all 3 samples (16.2 to 30.0 pg, 85%; 17.2 to 24.8 
pg, 44%; 22.0 to 30.5 pg, 39%) compared to untreated cells (Figure 7). Similarly, 
Figure 6. IL-17 production by anti-IL-23p19 antibody-treated, 
B. burgdorferi-stimulated spleen cells from 3 sham- or 
OspA-vaccinated, IL-10-deficient mice. 
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untreated, B. burgdorferi-stimulated cells from wild-type, OspA-vaccinated mice 
produced between 13.4 and 32.4 pg IL-17/mL supernatant after 24 hours. 
Stimulated cells from OspA-vaccinated mice treated with 10 µg/mL anti-CD4 
antibodies also exhibited an increase in IL-17 production in all 3 samples (13.4 to 
32.5 pg, 142%; 16.1 to 46.2, 187%; 32.4 to 56.8, 75%) after 24 hours of 
incubation (Figure 7). 
After 48 hours of incubation, untreated, B. burgdorferi-stimulated cells from wild-
type, sham-vaccinated mice produced between 21.9 and 52.1 pg IL-17/mL 
supernatant. Treatment of stimulated cells from sham-vaccinated mice with 10 
µg/mL anti-CD4 antibodies for 48 hours resulted in a decrease in IL-17 
production in 2 of the 3 samples (52.1 to 43.2 pg, 17%; 49.8 to 36.5 pg, 27%)  
compared to untreated cells. By contrast, in 1 of 3 samples, 10 µg/mL anti-CD4 
antibodies caused a 28% increase in IL-17 production (21.9 to 28.1 pg).(Figure 
7). Untreated, B. burgdorferi-stimulated cells from wild-type, OspA-vaccinated 
mice produced between 11.4 and 104.1 pg IL-17/mL supernatant after 48 hours 
of incubation. In contrast to cells from sham-vaccinated mice, stimulated cells 
from OspA-vaccinated mice treated with 10 µg/mL anti-CD4 antibodies for 48 
hours displayed a strong decrease in IL-17 production in 2 of the 3 samples (57.7 
to 18.2 pg, 68%; 104.1 to 4.0 pg, 96%) compared to untreated cells (Figure 7). 
IL-17 production was minimally increased (11.4 to 12.4 pg, 9%) in a third sample. 
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Cells were also treated with 20 µg/mL anti-CD4 antibodies. Untreated, B. 
burgdorferi-stimulated cells from wild-type, sham-vaccinated mice produced 
between 6.5 and 70.3 pg IL-17/mL supernatant after 24 hours. Treatment of 
stimulated cells from sham-vaccinated mice with 20 µg/mL anti-CD4 antibodies 
for 24 hours resulted in a decrease in IL-17 production in 2 of the 3 samples 
(36.5 to 16.4 pg, 55%; 70.3 to 12.9 pg, 82%) compared to untreated cells (Figure 
8). By contrast, in 1 of 3 samples, 20 µg/mL anti-CD4 antibodies caused a 92% 
increase in IL-17 production (6.5 to 12.5 pg). In addition, untreated, B. 
burgdorferi-stimulated cells from wild-type, OspA-vaccinated mice produced 
Figure 7. IL-17 production by B. burgdorferi-stimulated 
spleen cells from 3 sham- or OspA-vaccinated wild-type 
mice after treatment with 10 µg/mL anti-CD4 antibodies. 
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between 13.7 and 34.7 pg IL-17/mL supernatant after 24 hours. Stimulated cells 
from OspA-vaccinated mice treated with 20 µg/mL anti-CD4 antibodies for 24 
hours exhibited an increase in IL-17 production in 2 of 3 samples (13.7 to 15.6 
pg, 14%; 20.6 to 27.1, 32%) compared to untreated cells (Figure 8). By contrast, 
in 1 of 3 samples, 20 µg/mL anti-CD4 antibodies caused a slight decrease in IL-
17 production (34.7 to 31.9 pg, 8%). 
After 48 hours of incubation, untreated, B. burgdorferi-stimulated cells from 
sham-vaccinated wild-type mice produced between 11.7 and 23.6 pg IL-17/mL 
supernatant.  Treatment of B. burgdorferi-stimulated cells from sham-vaccinated 
mice with 20 µg/mL anti-CD4 antibodies for 48 hours resulted in an increase in 
IL-17 production in all 3 samples (11.7 to 27.3 pg, 133%; 12.7 to 33.6 pg, 165%; 
23.6 to 28.0 pg, 18%) compared to untreated cells (Figure 8). In addition, 
untreated, B. burgdorferi-stimulated cells from wild-type, OspA-vaccinated mice 
produced between 8.9 and 92.1 pg IL-17/mL supernatant. In contrast to cells 
from sham-vaccinated mice, stimulated cells from OspA-vaccinated mice treated 
with 20 µg/mL anti-CD4 antibodies for 48 hours displayed a decrease in IL-17 
production in all 3 samples (92.1 to 24.7 pg, 73%; 54.7 to 21.4 pg, 61%; 8.9 to 
8.2 pg, 8%) compared to untreated cells; in two of these samples, the reduction 
was substantial (Figure 8). 
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Effect of anti-CD4 antibodies on production of IL-17 by cells of OspA-vaccinated, 
IL-10-deficient mice. Spleen cells harvested from IL-10-deficient, sham- and 
OspA-vaccinated mice were incubated with B. burgdorferi and 10 µg/mL or 20 
µg/mL anti-CD4 antibodies for 24 or 48 hours. Untreated, B. burgdorferi-
stimulated cells from IL-10-deficient, sham-vaccinated mice produced between 
14.0 and 133.7 pg IL-17/mL supernatant after 24 hours. Treatment of stimulated 
cells from sham-vaccinated mice with 10 µg/mL anti-CD4 antibodies for 24 hours 
resulted in an increase of IL-17 production in 2 of 3 samples (14.0 to 28.0 pg, 
Figure 8. IL-17 production by B. burgdorferi-stimulated 
spleen cells from 3 sham- or OspA-vaccinated wild-type 
mice after treatment with 20 µg/mL anti-CD4 antibodies. 
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100%; 27.9 to 78.6 pg, 182%) compared to untreated cells (Figure 9). A third 
sample displayed a decrease in IL-17 production (133.7 to 86.9 pg, 35%) 
following treatment with 10 µg/mL anti-CD4 antibodies. Similarly, untreated, B. 
burgdorferi-stimulated cells from IL-10-deficient, OspA-vaccinated mice produced 
between 10.7 and 135.6 pg IL-17/mL supernatant after 24 hours. However, 
stimulated cells from OspA-vaccinated mice treated with 10 µg/mL anti-CD4 
antibodies for 24 hours exhibited a substantial decrease in IL-17 production from 
all 3 samples (135.6 to 19.7 pg, 85%; 93.0 to 50.7 pg, 45%; 10.7 to 2.0 pg, 81%) 
(Figure 9). 
After 48 hours of incubation, untreated, B. burgdorferi-stimulated cells from IL-10-
deficient, sham-vaccinated mice produced between 14.5 and 87.8 pg IL-17/mL 
supernatant. Treatment of stimulated cells from sham-vaccinated mice with 10 
µg/mL anti-CD4 antibodies for 48 hours resulted in slight increases in IL-17 
production in 2 of the 3 samples (87.8 to 91.7 pg, 4%; 14.5 to 15.5, 7%), but a 
decrease in IL-17 production in another sample (83.0 to 48.4 pg, 42%) compared 
to untreated cells (Figure 9). Similarly, untreated, B. burgdorferi-stimulated cells 
from IL-10-deficient, OspA-vaccinated mice produced between 8.5 and 69.5 pg 
IL-17/mL supernatant. Stimulated cells from OspA-vaccinated mice treated with 
10 µg/mL anti-CD4 antibodies for 48 hours displayed an increase in IL-17 
production in 2 of 3 samples (8.5 to 12.9 pg, 52%; 29.6 to 39.0 pg, 32%) 
compared to untreated cells. By contrast, in 1 of 3 samples, 10 µg/mL anti-CD4 
antibodies caused a 45% decrease in IL-17 production (69.5 to 39.0 pg). 
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Cells were also treated with 20 µg/mL anti-CD4 antibodies. Untreated, B. 
burgdorferi-stimulated cells from IL-10-deficient, sham-vaccinated mice produced 
between 1.4 and 86.6 pg IL-17/mL supernatant after 24 hours. Treatment of 
stimulated cells from sham-vaccinated mice with 20 µg/mL anti-CD4 antibodies 
for 24 hours resulted in an increase of IL-17 production in all 3 samples (1.4 to 
34.4 pg, 2357%; 34.8 to 67.7 pg, 95%; 86.6 to 103.0 pg, 19%) compared to 
untreated cells (Figure 10). Similarly, untreated, B. burgdorferi-stimulated cells 
from IL-10-deficient, OspA-vaccinated mice produced between 13.8 and 67.7 pg 
Figure 9. IL-17 production by B. burgdorferi-stimulated spleen 
cells from 3 sham- or OspA-vaccinated, IL-10-deficient mice 
after treatment with 10 µg/mL anti-CD4 antibodies. 
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IL-17/mL supernatant after 24 hours. However, stimulated cells from OspA-
vaccinated mice treated with 20 µg/mL anti-CD4 antibodies for 24 hours resulted 
in a decrease in IL-17 production in 2 of the 3 samples (67.7 to 58.3 pg, 14%; 
13.8 to 7.0 pg, 49%) compared to untreated cells (Figure 10). A third sample 
exhibited a 51% increase in IL-17 production (62.6 to 94.5 pg) compared to 
untreated cells. 
After 48 hours of incubation, untreated, B. burgdorferi-stimulated cells from IL-10-
deficient, sham-vaccinated mice produced between 23.1 and 109.9 pg IL-17/mL 
supernatant. Treatment of B. burgdorferi-stimulated cells from sham-vaccinated 
mice with 20 µg/mL anti-CD4 antibodies for 48 hours resulted in a decrease in IL-
17 production in 2 of 3 samples (109.9 to 45.0 pg, 59%; 63.2 to 59.2 pg, 6%), 
while one sample exhibited increased production of IL-17 (23.1 to 31.4 pg) 
compared to untreated cells (Figure 10). In addition, untreated, B. burgdorferi-
stimulated cells from IL-10-deficient, OspA-vaccinated mice produced between 
5.6 and 72.3 pg IL-17/mL supernatant. Stimulated cells from OspA-vaccinated 
mice treated with 20 µg/mL anti-CD4 antibodies for 48 hours also showed a 
decrease in IL-17 production in 2 of the 3 samples (32.1 to 19.2 pg, 41%; 5.6 to 
4.9 pg, 13%) compared to untreated cells, while 1 of 3 samples showed a slight 
increase (72.3 to 78.8 pg, 9%) in IL-17 production. 
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IL-23 production by spleen cells of OspA-vaccinated mice following stimulation 
with B. burgdorferi. No IL-23 was detected from cultures of spleen cells that were 
obtained from sham- or OspA-vaccinated wild-type mice, regardless of whether 
the cells were stimulated, treated with anti-cytokine or anti-CD4 antibodies, or 
incubated for 24 or 48 hours (not shown). Similarly, no IL-23 was detected from 
stimulated or treated spleen cells obtained from sham-vaccinated, IL-10-deficient 
mice.  
In addition, after 24 hours of incubation, no IL-23 was detected among 
unstimulated or B. burgdorferi-stimulated cells from OspA-vaccinated, IL-10-
Figure 10. IL-17 production by B. burgdorferi-stimulated 
spleen cells from 3 sham- or OspA-vaccinated, IL-10-deficient 
mice after treatment with 20 µg anti-CD4 antibodies. 
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deficient mice (not shown). No IL-23 was detected among cultures of stimulated 
spleen cells incubated with anti-IL-6 antibodies or 10 μg anti-CD4 antibodies, 
regardless of whether the cells were incubated for 24 or 48 hours. 
However, after 48 hours of incubation, IL-23 production was detected among 
unstimulated cells in 2 of 3 samples (29.3 and 8.6 pg/mL supernatant; Figure 11). 
Stimulation with B. burgdorferi caused a 100% reduction in IL-23 production from 
each sample. Cells from a third vaccinated mouse failed to produce IL-23, 
regardless of whether they were stimulated.  
After 24 hours of incubation with 20 μg/mL of isotype control antibodies, 
stimulated cells from OspA-vaccinated, IL-10-deficient mice produced IL-23 in 1 
of 3 samples (26.9 pg/mL supernatant; Figure 11, top). When cells from this 
mouse were treated with 20 μg/mL anti-CD4 antibodies for 24 hours, a 12% 
increase in IL-23 production from cells (26.9 to 30.1 pg) resulted. In addition, 
treatment with 20 μg/mL anti-CD4 antibodies caused the production of IL-23 
(16.2 pg/mL supernatant) from a sample that did not produce IL-23 when 
incubated with control antibodies. Cells from a third mouse failed to produce IL-
23 regardless of treatment. By contrast, no detectable IL-23 was produced by 
these cells after 48 hours of incubation (not shown). 
42 
 
 
 
 
 
 
 
 
 
II. Specific Aim 2:  Determine the ability of OspA to induce IL-17-dependent 
inflammation. 
Hind paw swelling of OspA-vaccinated mice after infection with B. burgdorferi. 
Uninfected, OspA-vaccinated wild-type mice exhibited mild hind-paw swelling 
after injection of BSK medium. A slight increase in swelling was observed at day 
3 after BSK injection, followed by a decrease to nearly baseline levels at day 6, 
with a slight increase again at day 8 (Figure 12). By contrast, hind-paw swelling 
in OspA-vaccinated, B. burgdorferi-infected wild-type mice was not observed until 
Figure 11. IL-23 production by B. burgdorferi-stimulated spleen 
cells from 3 OspA-vaccinated, IL-10-deficient mice after 
treatment with 20 µg/mL anti-CD4 antibodies for 24 hours (top). 
Effects of borrelial stimulation on IL-23 production after 48 
hours (bottom). 
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day 6 after infection. However, this increase in swelling at day 6 was comparable 
to the swelling observed in OspA-vaccinated, uninfected control mice. This 
swelling declined to nearly baseline measurements by day 8 after infection 
(Figure 12). In addition, OspA-vaccinated mice that were infected with B. 
burgdorferi and received treatments of anti-IL-17 antibodies exhibited a gradual 
increase in paw swelling until a peak at day 6 after infection, followed by a rapid 
decline well below the baseline measurements by day 8 after infection (Figure 
12). 
 
 
 
Similarly, OspA-vaccinated, B. burgdorferi-infected IL-10-deficient mice did not 
exhibit hind paw swelling until day 6 after infection. However, these paws then 
displayed a steep increase in swelling by day 8 (Figure 13). In addition, the hind 
paws of OspA-vaccinated, B. burgdorferi-infected, IL-10-deficient mice treated 
with anti-IL-17 antibodies were visibly swollen by day 3. Swelling steadily 
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Figure 12. Average change in hind paw swelling among OspA-vaccinated 
wild-type mice that were injected with BSK medium (dashed line, n=3), 
infected with B. burgdorferi (solid black line, n=4), and infected with B. 
burgdorferi and injected with anti-IL-17 antibodies (green line, n=4). 
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increased until day 8 after infection. Mice receiving anti-IL-17 antibodies 
displayed almost twice the increase in swelling of the untreated mice (Figure 13). 
Insufficient numbers of mice were available for OspA-vaccinated, uninfected 
controls. 
 
 
 
 
IL-17 production by spleen cells of OspA-vaccinated and B. burgdorferi-infected 
mice. Eight days after infection, spleen cells were harvested from OspA-
vaccinated mice that were not infected with B. burgdorferi, infected but not 
treated with anti-IL-17 antibodies, and infected and treated with anti-IL-17 
antibodies. After 4 hours of incubation in the absence of in vitro stimulation, no 
IL-17 was detected by cells of any of these mice, regardless of whether they 
were wild-type or IL-10-deficient (not shown).  
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Figure 13. Average change in hind paw swelling among OspA-
vaccinated, IL-10-deficient mice that were infected with B. 
burgdorferi and injected with anti-IL-17 antibodies (green line, n=3) 
or isotype control antibodies (black line, n=2). 
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After 24 hours of incubation, cells from uninfected, OspA-vaccinated wild-type 
mice produced no IL-17. Cells from 1 of 4 OspA-vaccinated, B. burgdorferi-
infected wild-type mice produced detectable IL-17 (25.8 pg/mL supernatant; data 
not shown). Two of 4 samples from OspA-vaccinated, B. burgdorferi-infected 
wild-type mice treated with anti-IL-17 antibodies produced detectable amounts of 
IL-17, but these values were low (12.1 and 13.7 pg/mL supernatant).  
In addition, no IL-17 was produced by cells of OspA-vaccinated, B. burgdorferi-
infected IL-10-deficient mice after 24 hours of incubation. Although cells from 1 of 
3 OspA-vaccinated, B. burgdorferi-infected IL-10-deficient mice treated with anti-
IL-17 antibodies produced detectable IL-17 (4.3 pg/mL supernatant), this was just 
slightly above the limits of detection. 
 
IL-23 production by spleen cells of OspA-vaccinated and B. burgdorferi-infected 
mice. After 4 hours of incubation, no IL-23 was detected among cells of any 
group of wild-type mice. In addition, cells from OspA-vaccinated, B. burgdorferi-
infected, IL-10-deficient mice did not produce detectable IL-23. By contrast, cells 
from 1 of 3 OspA-vaccinated, B. burgdorferi-infected IL-10-deficient mice treated 
with anti-IL-17 antibodies produced detectable IL-23 (33.0 pg/mL supernatant; 
data not shown). 
After 24 hours of incubation, cells from 1 of 4 OspA-vaccinated, B. burgdorferi-
infected wild-type mice produced detectable IL-23 (8.7 pg /mL supernatant). No 
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IL-23 was detected among cells from uninfected OspA-vaccinated mice or OspA-
vaccinated and B. burgdorferi-infected mice treated with anti-IL-17 antibodies. In 
addition, cells from 1 of 3 OspA-vaccinated, B. burgdorferi-infected IL-10-
deficient mice produced detectable IL-23 (8.8 pg/mL supernatant) after 24 hours 
of incubation. However, this was just slightly above the limits of detection. OspA-
vaccinated, B. burgdorferi-infected, IL-10-deficient mice treated with anti-IL-17 
antibodies did not produce detectable IL-23 after 24 hours of incubation (not 
shown).  
 
Borrelicidial antibody titers following OspA vaccination and infection with B. 
burgdorferi. Blood was obtained from IL-10-deficient, OspA-vaccinated, B. 
burgdorferi-infected mice that were untreated or treated with anti-IL-17 antibodies 
to assess the relative amounts of serum antibodies with the ability to kill B. 
burgdorferi 297. As expected, OspA-vaccinated, IL-10-deficient mice infected 
with the spirochete were found to have high borrelicidal antibody titers (greater 
than 40,960; Figure 14) 8 days after infection. By contrast, treatment of OspA-
vaccinated, B. burgdorferi-infected, IL-10-deficient mice with anti-IL-17 antibodies 
resulted in an antibody titer of 1280 (a reduction of at least 32-fold) 8 days after 
infection. Serum from groups of wild-type mice produced inconclusive results 
(data not shown). A control group with immune serum, spirochetes, and no 
complement did not yield an antibody titer, nor did a control group containing 
serum from wild-type, sham-vaccinated mice. 
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Figure 14. Serum borreliacidal antibody titers of OspA-vaccinated, 
B. burgdorferi-infected, IL-10-deficient mice treated with either 
anti-IL-17 antibodies or isotype control antibodies. 
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CHAPTER 4: DISCUSSION 
 
Arthritis is a common symptom of patients infected with B. burgdorferi and can 
have serious effects on the quality of life for those living with the condition. 
Although OspA was the main candidate for a human vaccine component, 
previous studies have shown that OspA-reactive Th1 cells are present in patients 
with Lyme arthritis (Gross et al. 1998). In addition, hamsters vaccinated with 
OspA and challenged with B. burgdorferi displayed severe, destructive arthritis 
(Croke et al. 2000). These studies, and others, suggest that the immunodominant 
antigen OspA is a potent inducer of inflammation. 
As with Th1 cells, evidence exists that Th17 cells are likely involved in the 
development of Lyme arthritis in animal models and humans (Nardelli et al. 
2008a; Codolo et al. 2008). Blockage of IL-17 has been shown to inhibit the 
severity of Lyme arthritis (Burchill et al. 2003; Nardelli et al. 2004, Nardelli et al. 
2008b), particularly in the absence of a Th1 response. In addition, it has been 
found that IL-23, a survival factor for Th17 cells, stimulates the production of IL-
17 following B. burgdorferi infection and assists in the induction of Lyme arthritis 
in a mouse model (Kotloski et al. 2008). Further investigation into the 
mechanisms of the IL-17 response to B. burgdorferi OspA may provide a better 
understanding of the immune response that leads to Lyme arthritis, as well as 
considerations for potential vaccines for Lyme disease. The objective of this 
thesis was to provide further characterization of the immune response to B. 
burgdorferi OspA. 
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The hypothesis of this thesis was: Vaccination with OspA will predispose mice to 
developing a Th17 cell response and IL-17-dependent hind paw swelling 
following stimulation with live spirochetes. This hypothesis was tested by 
pursuing the following specific aims: 
 
I. Specific Aim 1: Determine the ability of OspA to induce a Th17 response. 
The working hypothesis of this specific aim was: Vaccination with OspA will 
prime mice to produce a Th17 cell response following stimulation with B. 
burgdorferi. In order to determine the relationship OspA has in the induction of IL-
17 and related cytokines in Lyme arthritis, mice were vaccinated with OspA and 
euthanized after two or three weeks, and spleen cells were incubated in the 
absence or presence of B. burgdorferi and with various antibody treatments. 
Given that wild-type C57BL/6 mice are well known to be resistant to developing 
Lyme arthritis, we expected that cells of sham-vaccinated wild-type mice would 
produce a mild Th17-related response when stimulated with B. burgdorferi. 
However, we anticipated that with the longer the incubation, the more likely a 
Th17-like response would occur. In addition, we expected that cells of OspA-
vaccinated wild-type mice would produce a moderate Th17-like response after 
stimulation. This was based on previous studies using C57BL/6 mice vaccinated 
with whole B. burgdorferi cells (Nardelli et al. 2008b). Furthermore, we expected 
that in IL-10-deficient mice, a greater Th17 response would occur among cells of 
both sham- and OspA-vaccinated mice, respectively. This was based on recent 
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findings that C57BL/6 mice lacking IL-10 develop IL-17-dependent inflammation 
after infection with B. burgdorferi (Hansen et al. 2013).  
First, we expected to see an increase in IL-17 production by cells of sham-
vaccinated wild-type mice when stimulated with B. burgdorferi. This would be 
consistent with previous findings in which naïve, wild-type murine splenic cells 
stimulated with B. burgdorferi produced more IL-17 than cells that remained 
unstimulated (Hansen et al. 2013). Surprisingly, IL-17 production decreased 
substantially in 2 of the 3 sham-vaccinated mice when stimulated with B. 
burgdorferi, while cells from the third mouse exhibited a slight increase in IL-17 
production, after 24 hours (Figure 1). However, after 48 hours of incubation, we 
observed the expected trend of increased IL-17 production in the presence of B. 
burgdorferi: stimulation of cells from 2 of 3 mice induced notable (≥ 55%) 
production of IL-17. While our results from these 24-hour samples were 
unexpected, these particular findings from Hansen et al. (2013), showing 
increased IL-17 production with B. burgdorferi stimulation of naïve cells, were 
actually not statistically significant. Additionally, wild-type C57BL/6 mice are less 
susceptible to Lyme arthritis than other strains, likely due to increased IL-10 
production (Lazarus et al. 2008), which could decrease IL-17 production during 
early B. burgdorferi exposure.  
Stimulated cells from OspA-vaccinated wild-type mice were expected to produce 
a larger amount of IL-17, as seen in previous studies in our lab using whole cell 
vaccines of B. bissettii followed by B. burgdorferi stimulation in vitro (unpublished 
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data). Despite these previous findings, cells from all 3 OspA-vaccinated wild-type 
mice had decreased IL-17 production at 24 hours after B. burgdorferi stimulation 
and robust IL-17 production at 48 hours (Figure 1, right). These trends are 
consistent with results seen among cells of sham-vaccinated wild-type mice at 24 
and 48 hours (Figure 1, left), again suggesting that an early anti-inflammatory 
response (possibly IL-10) may be important in initial decreases in IL-17 
production following B. burgdorferi stimulation, before subsequent inflammatory 
events occur. Importantly, IL-17 levels were increased more substantially at 48 
hours among stimulated cells from OspA-vaccinated mice than in those of sham-
vaccinated mice. This considerably increased level of IL-17 production in OspA-
vaccinated mice supports our hypothesis. This increased level of IL-17 
production among OspA-vaccinated cells was expected, as T cells are most 
likely primed in response to the OspA vaccine, leading to a more robust IL-17 
response from Th17 cells. This is supported by previous findings that individuals 
with persisting Lyme arthritis have reactive T cells, some of which are OspA-
specific, to B. burgdorferi (Gross et al. 1998). 
Similarly, we expected that cells from IL-10-deficient, sham-vaccinated mice 
would have increased IL-17 production following stimulation with B. burgdorferi, 
as seen in previous experiments in our lab (unpublished data). While the IL-17 
levels were not as high as we expected, 2 of the 3 mice displayed increases in 
IL-17 production following B. burgdorferi stimulation at 24 hours, and cells in all 3 
samples showed greatly increased IL-17 (47%-121%) production at 48 hours 
(Figure 2).  These findings support the idea that an initial decrease in IL-17 
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production following early stimulation of wild-type cells may be due to the 
presence of IL-10. IL-17-producing cells may be able to be activated earlier in IL-
10-deficient mice (24 hours) than in wild-type mice (48 hours). 
Supporting our hypothesis, cells from OspA-vaccinated, IL-10-deficient mice 
generally displayed an increase in IL-17 production following B. burgdorferi 
stimulation at 24 hours. Stimulated cells from 2 of 3 mice exhibited substantial 
increases in production of IL-17 (Figure 2, right), while the third sample exhibited 
a minor decrease in production. These results were expected due to the previous 
results obtained in our lab with whole organism vaccination of IL-10-deficient 
mice (unpublished data), which resulted in large amounts of IL-17 after 24 hours 
of incubation. These results can again be attributed to immune cells, possibly T 
cells, already being primed to the OspA protein on B. burgdorferi. In addition, we 
anticipated that cells from OspA-vaccinated, IL-10-deficient mice would show an 
even greater production of IL-17 at 48 hours following stimulation with B. 
burgdorferi. However, unexpectedly, cells from 2 of 3 mice displayed decreased 
IL-17 production following stimulation with B. burgdorferi, while the third sample 
exhibited a dramatic increase in IL-17 production. These results could be varied 
due to the small sample size. However, Hansen et al. (2013) also showed that 
cells from IL-10-deficient mice infected with B. burgdorferi for 1 day may down-
regulate IL-17 production following stimulation. This suggests that anti-
inflammatory mechanisms may inhibit the IL-17 response independently of IL-10 
(Hansen et al. 2013).  
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In order to determine whether OspA primes mice to develop a Th17-associated 
response, we incubated sham- and OspA-vaccinated spleen cells in the 
presence of B. burgdorferi and anti-IL-6 antibodies for 24 and 48 hours. We 
expected cells from sham-vaccinated and OspA-vaccinated wild-type mice to 
produce less IL-17 following interaction with anti-IL-6 antibodies, as IL-6 is a 
significant contributor to the differentiation of Th17 cells (Bettelli et al. 2006). 
Unexpectedly, we observed a considerable increase in IL-17 production after 24 
hours in the presence of anti-IL-6 antibodies in cultures of both sham-vaccinated 
(2 of 3 mice) and OspA-vaccinated (3 of 3) wild-type mouse spleen cells (Figure 
3). However, after 48 hours, IL-17 production decreased among cells of 2 of the 
3 sham-vaccinated mice, while the third sample showed a minimal increase in IL-
17 production (Figure 3). Importantly, cells from 2 of 3 OspA-vaccinated wild-type 
mice showed substantial decreases of IL-17 in the presence of anti-IL-6 
antibodies (Figure 3), although the third showed a notable increase in IL-17 
production. 
One explanation for these results could be that a discernible effect of anti-IL-6 
antibodies isn’t achieved until 48 hours of incubation due to IL-6 possibly being 
highly expressed among our whole spleen cell cultures. In support of this, OspA 
has been shown to stimulate the production of IL-6 (Häupl et al. 1997). These 
results could also be explained by two findings involving IL-6 and inflammatory T 
cells. The Th17-associated cytokine interleukin-21 (IL-21) has been shown to 
work in tandem with TGF-β in IL-6-deficient mice to induce Th17 cell 
differentiation (Korn et al. 2007). It is possible that when IL-6 is initially blocked 
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by antibodies in samples incubating for 24 hours, IL-21 may act to circumvent the 
loss of IL-6 in aiding production of IL-17.  As the cells are stimulated for a longer 
period of time (48 hours), the requirement of IL-6 in stimulating Th17 cell 
differentiation could be more pronounced, although not absolutely required. At 
this time, blocking IL-6 may result in inhibition of IL-17, yet residual IL-17 
production could be accounted for by a combination of IL-21 and TGF-β. Yet 
another possibility could be that Th1 cells are initially downregulated by anti-IL-6 
antibodies (Guggino et al. 2014) in the 24-hour sample, which may cause an 
increase in Th17 cells, leading to increased IL-17 production. This latter 
hypothesis is supported by the finding that Th17 cells and Th1 cells can have 
reciprocal developmental pathways (Yoshimura et al. 2006). If one cell type is 
affected by a loss of IL-6 activity, the other cell type could increase activity as 
compensation. 
Moreover, we expected, and observed, spleen cells from IL-10-deficient mice to 
produce higher levels of IL-17 overall than wild-type mice, even when treated 
with anti-IL-6 antibodies. We expected this because the IL-10-deficient mice most 
likely have fewer anti-inflammatory cells to downregulate an inflammatory 
response. Despite this, we also expected to observe a decrease in IL-17 
production in stimulated cells from IL-10-deficient mice after treatment with anti-
IL-6 antibodies. Generally, the trend among cells of sham-vaccinated, IL-10- 
deficient mice treated with anti-IL-6 antibodies were the same that of wild-type 
mice at 24 and 48 hours. However, we expected cells from OspA-vaccinated, IL-
10-deficient mice to produce lower levels of IL-17 following anti-IL-6 antibody 
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treatment at both 24 and 48 hours than sham-vaccinated mice. This tended to 
occur (Figure 4), supporting the notion that in the absence of IL-10, OspA 
stimulates a robust Th17 cell-associated response that could be inhibited by 
blocking IL-6. After 24 hours, we observed substantial decreases in IL-17 
production upon blocking IL-6 in these cultures of stimulated, OspA-vaccinated, 
IL-10-deficient cells (Figure 4). Surprisingly, IL-17 production increased in cells of 
one mouse. However, the initial production of IL-17 in this sample was minimal, 
and the resulting increase still yielded a low amount of IL-17 (14 pg/mL 
supernatant). Similarly, by 48 hours, we observed decreases in IL-17 production 
by cells of 2 animals (Figure 4). Again, in a third mouse, initial IL-17 levels were 
low, and the resulting increase was also relatively low. Collectively, these 
findings also support our hypothesis that OspA can prime mice for a Th17-
associated response. 
Additionally, as IL-23 is a survival factor for Th17 cells (Bettelli et al. 2006), we 
incubated OspA-primed cells in the presence of anti-IL-23 antibodies to test 
whether the borrelial protein stimulates a Th17 response. We expected to 
observe a decrease in IL-17 production upon incubation with anti-IL-23 
antibodies. As expected, after 24 and 48 hours of incubation in the presence of 
B. burgdorferi and anti-IL-23p19 antibodies, cells from sham-vaccinated wild-type 
mice generally exhibited reduced production of IL-17 (Figure 5, left). One 
exception was a slight increase at 24 hours, which could be due to a delay in 
antibodies binding to IL-23; by 48 hours, cells from this mouse also experienced 
a decline in IL-17 production (Figure 5, left). We also expected to observe a 
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decrease in IL-17 production following the addition of anti-IL-23 antibodies to 
cells of wild-type, OspA-vaccinated mice. After 24 hours, IL-17 production by 
cells of OspA-vaccinated wild-type mice declined with the addition of anti-IL-23 
antibodies in 2 of the 3 samples, with a slight increase in the third sample. 
Importantly, after 48 hours, we observed a consistent, substantial decrease of IL-
17 in all 3 samples treated with anti-IL-23 antibodies (Figure 5, right). This 
supports our hypothesis that OspA primes mice for a potent Th17 response.  
In addition, as expected, cells from OspA-vaccinated, IL-10-deficient mice 
showed substantial reductions in IL-17 upon blocking IL-23. These cells showed 
decreases of 37%, 78%, and 85% in IL-17 production after 24 hours and 
decreases of 61% and 71% after 48 hours (Figure 6, right). An exception 
occurred among cells from one mouse after 48 hours; although production of IL-
17 increased from 8.2 pg/mL to 20.6 pg/mL in the presence of anti-IL-23 
antibodies, the overall levels were very low, particularly for IL-10-deficient mice. 
In addition, the overall reductions in IL-17 due to blocking IL-23 among IL-10-
deficient OspA-vaccinated cells were much more dramatic than that which 
occurred among cells from sham-vaccinated, IL-10-deficient mice (Figure 6, left) 
and OspA-vaccinated wild-type mice (Figure 5, right). These findings support our 
hypothesis that OspA primes for a Th17 response and support previous studies 
on the involvement of IL-23 in increased Th17 activity in the context of B. 
burgdorferi infection (Knauer et al. 2007; Kotloski et al. 2008; Oosting et al. 
2011). Consideration of the role of IL-23 in Lyme arthritis is important, as 
elevated levels of IL-23 are observed in patients with Lyme arthritis (Strle et al. 
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2014), and borrelial NapA is able to elicit increased levels of IL-23 in human 
synovial cells (Codolo et al. 2008).  
Finally, in order to determine whether CD4+ cells served as a source of IL-17 
production in response to OspA, cells from sham-vaccinated and OspA-
vaccinated mice stimulated with B. burgdorferi were treated with either 10 µg/mL 
or 20 µg/mL anti-CD4 antibodies. The main types of CD4+ T cells include 
inflammatory Th1 and Th17 cells, as well as anti-inflammatory Th2 and T 
regulatory (Treg) cells. We expected to observe a decrease in IL-17 production in 
cultures of cells with anti-CD4 antibodies, regardless of the strain of mouse. 
Surprisingly, cells from sham-vaccinated and OspA-vaccinated wild-type mice 
expressed increased levels of IL-17 following administration of 10 µg/mL anti-
CD4 antibodies at 24 hours (Figure 7).  However, IL-17 production was 
decreased in 2 of 3 samples after 48 hours. While unexpected, these findings at 
24 hours may be the result of anti-CD4 antibodies binding mainly Th2 or Treg 
cells, which would allow inflammatory cells such as Th17 cells to thrive. 
Additionally, Th1 cells also could have been blocked more readily than Th17 
cells, allowing Th17 cells to be upregulated due to a potentially reciprocal 
developmental relationship (Yoshimura et al. 2006). This may have allowed Th17 
cells to predominate during stimulation and early blockage with 10 μg/mL of anti-
CD4 antibodies. As OspA induces a Th1 response, blockage of Th1 cells, 
leading to increased Th17 activity, could explain the dramatic increase in IL-17 
production by the vaccine-primed, stimulated cells (Figure 7, upper right).  
However, after 48 hours, the substantial decline in IL-17, particularly among 
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vaccine-primed cells (Figure 7, lower right), may have been the result of anti-CD4 
antibodies acting in a more widespread manner, eventually ceasing the 
production of IL-17 from Th17 cells.  
With the treatment of 20 µg anti-CD4 antibodies, cells from sham-vaccinated 
wild-type mice expectedly decreased production of IL-17 after 24 hours, but then, 
surprisingly, increased production after 48 hours (Figure 8). With twice the dose 
of antibodies, it may be that a larger portion of all T cells (including Th17 cells) 
were prevented from functioning at 24 hours. With regard to the increase of IL-17 
observed among the 48-hour sham-vaccinated wild-type cells, it appears that the 
borrelial stimulation did not induce IL-17 production as abundantly it did after 24 
hours. Importantly, cells from OspA-vaccinated wild-type mice treated with 20 
µg/mL anti-CD4 antibodies for 24 hours displayed only slight increases in IL-17 
production in 2 of the 3 samples (Figure 8, upper right); the differences between 
stimulated and antibody-treated cells were minimal. By contrast, after 48 hours, 
anti-CD4 antibody-treated cells exhibited a dramatic reduction in IL-17 production 
(Figure 8, lower right). This suggests that CD4+ cells are a potent source of IL-17 
in OspA-vaccinated mice. As these cells would likely be Th17 cells, this lends 
support to our hypothesis.  
We also expected cells from IL-10-deficient mice to decrease their production of 
IL-17 after treatment with anti-CD4 antibodies at both 10 µg/mL and 20 µg/mL, 
for the same reasons stated above. We particularly expected a dramatic 
decrease in IL-17 levels with treatment of OspA-vaccinated, stimulated cells with 
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anti-CD4 antibodies, since we hypothesized that these mice would display a 
robust Th17 cell response. Unexpectedly, cells from sham-vaccinated, IL-10-
deficient mice exhibited a general trend of increased IL-17 production when 
treated with 10 µg/mL of anti-CD4 antibodies after 24 hours of incubation. We 
also observed a decrease in IL-17 by one sample at 48 hours, while the other 
two samples had minimal changes in IL-17 production (Figure 9, left). These 
findings may be supported by a study demonstrating that mice deficient in IL-10 
exhibit inflammation to B. burgdorferi infection due to increased Th1 cell activity 
(Sonderegger et al. 2012). As described previously, in the event that a high 
number of Th1 cells are preferentially inhibited by anti-CD4 antibodies, Th17 
cells may be upregulated to compensate for the partial Th1 cell loss (Yoshimura 
et al. 2006); however, a Th17 response may still predominate in individual 
samples. After 48 hours of incubation, the decrease or minimal increases seen 
(Figure 9, lower left) may be the cause of anti-CD4 antibodies having more time 
to exert their effects on all T cells. By contrast, cells from OspA-vaccinated, IL-
10-deficient mice exhibited a steep decline in IL-17 production after 24 hours of 
incubation with 10 µg/mL of anti-CD4 antibodies (Figure 9, right), which strongly 
supports our hypothesis. However, a slight increase in IL-17 production was 
unexpectedly observed in 2 of 3 samples after 48 hours of incubation with 10 
µg/mL anti-CD4 antibodies. Importantly, though, the level of IL-17 in these two 
untreated cell samples at 48 hours was unusually low initially, and the increase in 
total IL-17 production by these groups was also low. By contrast, the third sample 
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of cells, which produced more IL-17, exhibited a 45% reduction in IL-17 
production (Figure 9, right). 
Stimulated cells from sham-vaccinated and OspA-vaccinated, IL-10 deficient 
mice treated with 20 µg/mL anti-CD4 antibodies also were expected to display 
reduced IL-17 production.  Cells from sham-vaccinated mice developed 
increased IL-17 levels following treatment with antibodies after 24 hours (Figure 
10, left), and then exhibited mixed results at 48 hours; both results were 
unexpected. As previously suggested, Th1 cells would likely be in greater 
number than Th17 cells in IL-10-deficient mice due to the lack of the anti-
inflammatory cytokine and the overall abundance of Th1 cells. Again, Th1 cells 
may have been preferentially blocked, leading to increased IL-17 production. In 
addition, the decrease in IL-17 levels in 2 of the 3 samples, and the relatively low 
level of IL-17 in the third sample, at 48 hours may reflect a more global blocking 
of inflammatory T cells that occurred with more time. Additionally, cells from 
OspA-vaccinated, IL-10-deficient mice treated with 20 µg/mL anti-CD4 antibodies 
displayed decreased IL-17 production in 2 of the 3 samples at 24 hours, as well 
as at 48 hours. Overall, this trend supports what we expected to see when 
stimulated cells from OspA-vaccinated, IL-10-deficient mice are treated with anti-
CD4 antibodies. 
Collectively, our hypothesis stating that OspA-vaccinated mice will be 
predisposed to developing a Th17 response following stimulation with B. 
burgdorferi is supported by OspA-vaccinated wild-type mice exhibiting 
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dramatically decreased IL-17 production following treatment with anti-CD4 
antibodies after 48 hours of incubation. In addition, the strong decrease in IL-17 
production by cells from OspA-vaccinated, IL-10-deficient mice at 24 hours also 
supports our hypothesis. We would expect Th17 activity to be observed earlier in 
IL-10-deficient mice, and the earlier times at which IL-17 was reduced by anti-
CD4 antibodies supports this. 
To further elucidate the role of Th17 cells in the response to OspA, cells from 
OspA-vaccinated wild-type and IL-10-deficient mice were measured for levels of 
IL-23, an important cytokine for Th17 cell survival. We expected to see increased 
IL-23 levels when cells were stimulated with B. burgdorferi and decreased IL-23 
levels following treatment with Th17-associated antibodies in OspA-vaccinated 
mice. These expectations were based on several previously mentioned studies 
involving both human and mouse models of B. burgdorferi infection. We 
expected an initial increase in IL-23 production upon stimulation with B. 
burgdorferi, as IL-23 has been shown to be produced following stimulation of 
bacterial products in vitro (Aggarwal et al. 2003). Additionally, it is known that IL-
23 is essential to IL-17 production, particularly in the context of B. burgdorferi 
(Knauer et al. 2007, Kotloski et al. 2008). Surprisingly, we observed very little IL-
23 production in our in vitro cultures of vaccinated mouse spleen cells. The only 
samples that displayed any IL-23 were unstimulated cells from OspA-vaccinated 
IL-10-deficient mice at 48 hours, and stimulated OspA-primed cells treated with 
20 µg/mL anti-CD4 antibodies. While unexpected, it is likely that the cell types 
that produce IL-23, such as dendritic cells and (especially) neutrophils, were not 
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present in large quantities in our samples. It is also possible that in our model, 
very little IL-23, possibly below the ELISA detection threshold, is needed to 
maintain a population of Th17 cells in the murine spleen. In addition, it is possible 
that secreted IL-23 bound to target cells rapidly, such that detection of the 
cytokine in supernatants was not possible. These results do not support our 
hypothesis that OspA-vaccinated mice are predisposed to developing Th17 
responses to stimulation with B. burgdorferi. To better elucidate the activity of IL-
23, future studies could involve determining levels of IL-23 gene transcription. 
We were also interested in determining levels of Th17-associated cytokines in 
mice that were vaccinated with OspA and subsequently infected with B. 
burgdorferi without any further stimulation in vitro. The purpose of this was to 
evaluate the intrinsic cytokines being produced in response to in vivo B. 
burgdorferi stimulation following OspA vaccination and also to evaluate how 
current levels of inflammatory cytokines may reflect paw swelling. We expected 
to see relatively high levels of IL-17 and IL-23 production by cells of these mice, 
based on previous studies determining a significant IL-17 and IL-23 response in 
both humans and mice infected with B. burgdorferi (Infante-Duarte et al. 2000, 
Codolo et al. 2008, Strle et al. 2014). Unexpectedly, there was very little IL-17 
and IL-23 measured in our samples. These results do not support the hypothesis 
that OspA vaccination predisposes mice to developing a Th17 response following 
B. burgdorferi stimulation. It is possible that in this experiment, Th17-associated 
events occurred primarily in the days soon after infection, with the Th17 response 
subsiding by day 8 after challenge.   
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II. Specific Aim 2: Determine the ability of OspA to induce IL-17-dependent 
inflammation.  
The working hypothesis of this specific aim was: Vaccination with OspA will 
prime mice to develop IL-17-dependent paw swelling after infection with B. 
burgdorferi. In order to determine if OspA could prime mice for IL-17-dependent 
inflammation, some OspA-vaccinated mice were infected and then treated with 
anti-IL-17 antibodies. We vaccinated with a protein of the infection strain due to 
reports that the protective OspA response wanes relatively quickly (Padilla et al. 
1994). Based on previous findings, we expected to observe a lower level of 
swelling in mice treated with anti-IL-17 antibodies than in untreated mice. 
However, hypothesis was only partially supported. We observed mild hind paw 
swelling among OspA-vaccinated, wild-type C57BL/6 mice infected with B. 
burgdorferi. When these mice were treated with anti-IL-17 antibodies, the degree 
of swelling decreased substantially by day 8 after infection, to below baseline 
levels (Figure 12). This supports our hypothesis, as well as previous studies 
using whole-Borrelia vaccines (Burchill et al. 2003; Nardelli et al. 2004; Nardelli 
et al. 2008b). This also supports findings by Hansen et al. (2013), in which anti-
IL-17 antibody treatment reduced swelling in non-vaccinated mice infected with 
B. burgdorferi. However, it is possible that vaccine-induced protective antibodies 
against the homologous infection did not wane, leading to a low amount of 
swelling, particularly in the arthritis-resistant phenotype.  
By contrast, we observed greater hind paw swelling in OspA-vaccinated, B. 
burgdorferi-infected, IL-10-deficient mice administered anti-IL-17 antibodies than 
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untreated mice (Figure 13). This does not support our hypothesis; however, 
these data were obtained using a small number of mice (three were treated; two 
were untreated), so they are not statistically significant. Regardless, these 
findings were not expected. Our laboratory has observed that blocking IL-17 
reduces swelling in infected IL-10-deficient mice that were previously vaccinated 
with whole B. burgdorferi (unpublished data). It is possible that OspA stimulates a 
significant amount of IL-17, and the amount of anti-IL-17 antibodies that was 
injected was insufficient to prevent swelling. In support of this, antibodies were 
administered every other day, while in previous studies, they were administered 
daily. These data were particularly surprising, given that swelling increased 
dramatically. Although OspA titers have been shown to wane relatively quickly 
after vaccination (Padilla et al. 1994), we would not have been surprised to have 
seen minimal swelling. Indeed, we observed the borreliacidal antibody response 
to be very high among these untreated mice (Figure 14). 
This may point to an important role of IL-10 and IL-17 together in controlling the 
effects of the antibody response to OspA. In order for neutralization of infection 
with B. burgdorferi to occur, a robust borreliacidal antibody response is 
necessary. Directly transferred Th17 cells into naïve mice have been shown to 
induce autoreactive antibodies resulting in experimentally-induced arthritis 
(Jacobs et al. 2009), suggesting that a Th17-like response to OspA early after 
infection could have promoted swelling through a mechanism independent of 
sustained infection. We anticipated the production of borreliacidal antibodies to 
be slightly, but not significantly, greater in IL-10-deficient mice than in wild-type 
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mice by day 8 after infection, as seen in previous experiments in our lab (Hansen 
et al. 2013). As observed in specific aim 1 of this study, IL-10-deficient mice 
tended to produce greater levels of IL-17, and they develop more pronounced 
swelling following OspA vaccination and B. burgdorferi infection, than their wild-
type counterparts. It is possible that the production of borreliacidal antibodies 
was affected in IL-10-deficient mice due to an early increased Th17 cell 
presence. However, due to inconclusive results with our wild-type mice, we were 
unable to compare antibody titers between wild-type and IL-10 deficient mice.  
Finally, untreated IL-10-deficient, OspA-vaccinated and B. burgdorferi-infected 
mice demonstrated borreliacidal activity in the greatest dilution that was 
performed, 1:40,960 (Figure 14), suggesting that the antibody titer for this group 
of mice may have been even higher. Administration of anti-IL-17 antibodies to 
these B. burgdorferi-infected, OspA-vaccinated, IL-10-deficient mice lessened 
their ability to produce antibody titers against B. burgdorferi that would appear to 
be protective. This supports findings that IL-17 is involved in the development of 
the antibody response (Jacobs et al. 2009; Blaho et al. 2009). A reduction in 
borreliacidal antibody titers among these anti-IL-17 antibody-treated mice may 
account for the increased swelling of their paws. Histopathological examination of 
these paws is required to confirm whether the swelling we observed reflects true 
arthritis. 
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CHAPTER 5: CONCLUSION AND FUTURE DIRECTIONS 
 
The hypothesis for this thesis was that vaccination with B. burgdorferi OspA will 
predispose mice to developing a Th17 cell response and IL-17-dependent hind 
paw swelling following stimulation with live spirochetes. The first specific aim of 
this study, to determine the ability of OspA to induce a Th17 response, was 
supported. Cells from OspA-vaccinated mice produced potent Th17 responses 
when stimulated with B. burgdorferi, which is supported by the decrease in IL-17 
production when these cells were treated with antibodies to Th17 cell-associated 
cytokines. These effects were typically more notable compared to those seen in 
cells of sham-vaccinated mice, pointing to a particular effect of OspA priming. In 
addition, these effects were especially notable among cells from IL-10-deficient 
mice, pointing to a regulatory role for IL-10 in the Th17-like response to OspA. 
Data collected in this study support previous findings involving Th17 activity in 
the pathogenesis of Lyme arthritis. Our results suggest the presence of primed, 
OspA-reactive Th17 cells in mice following vaccination with OspA. Isolation of 
OspA-specific Th17 cells in this murine model could further clarify the impact 
OspA has on Th17 activity. In addition, larger sample sizes are required to 
provide statistical significance to our findings, and cells could be incubated for up 
to 96 hours to provide a wider picture of the activity of putative Th17 cells. 
In order to further elucidate mechanisms of the Th17 response to OspA, the role 
of IL-21 in the presence and absence of IL-6 should be examined. IL-21 has 
been shown to act in a similar manner as IL-6, in that it also can induce the 
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differentiation of Th17 cells. In addition, the roles of Th1, Th2, and Treg cells on 
modulating the OspA-specific Th17 response should be examined by 
determining their associated cytokine responses. Understanding these 
relationships will help clarify the mechanisms by which B. burgdorferi proteins 
stimulate T cell-mediated inflammatory responses. 
The second specific aim of this study, to determine the ability of OspA to induce 
IL-17-dependent inflammation, was partially supported. Due to the small sample 
sizes, we cannot determine whether the results observed in this study are 
consistent and significant. We speculate that Th1 cell activity could be affecting 
Th17 cell activity in our in vivo OspA-vaccination/B. burgdorferi-infection model. 
Assessing IFN-γ levels in these mice could help determine whether Th1 and 
Th17 cells have supporting or opposing interactions in this system. It is possible 
that the main inflammatory events in vivo occur during the first few days after 
infection. Future experiments should include an examination of levels of Th17-
associated cytokines soon after infection. This response could also be further 
elucidated by identifying Th17 cells using flow cytometry. In addition, further 
examination of the interactions between IL-17, IL-10, and the borreliacidal 
antibody response is necessary. This interaction would likely include other Th17-
associated cytokines, including IL-6, TGF-β, and IL-21. 
In conclusion, we provide evidence that exposure to OspA may prime mice for 
the development of a Th17 response that is modulated by IL-10. Whether these 
in vitro results translate to in vivo conditions requires additional examination. 
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However, our findings provide the groundwork for considering novel immune 
mechanisms that should be considered in developing future vaccines for Lyme 
disease and therapeutic measures for people suffering from Lyme arthritis. 
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